<DOC>
	<DOCNO>NCT02833844</DOCNO>
	<brief_summary>The study divide 2 part . The first part study double-blinded last 24 week . During time , subject randomize ratio 2:1 receive either Repatha ( evolocumab ) QM placebo QM . The second part study 24-week open label extension period . During time subject receive Repatha ( evolocumab ) QM . The clinical hypothesis subcutaneous Repatha ( evolocumab ) QM well tolerate result great reduction LDL-C , define percent change baseline week 24 , compare placebo QM HIV-positive subject hyperlipidemia mixed dyslipidemia .</brief_summary>
	<brief_title>Safety , Tolerability &amp; Efficacy LDL-C Evolocumab Subjects With HIV &amp; Hyperlipidemia/Mixed Dyslipidemia</brief_title>
	<detailed_description>LDL-C = low density lipoprotein cholesterol QM = monthly Double blind = neither subject , site staff Sponsor study team know whether subject receive either evolocumab placebo Open label = subject receive evolocumab</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Male female ≥ 18 year age Known HIV ( human immunodeficiency virus ) infection stable HIV therapy ≥ 6 month Cluster differentiation 4 ( CD4 ) ≥ 250 cells/mm3 ≥ 6 month HIV viral load ≤ 50 copies/mL screen ≤ 200 copies/mL ≥ 6 month Subject stable lipidlowering therapy ≥ 4 week prior randomization expect change duration study For subject know clinical astherosclerotic CVD ( ASCVD ) , fast LDLC ≥ 70 mg/dL nonHDLC ≥ 100 mg/dL . For subject without know clinical ASCVD : fasting LDLC ≥ 100 mg/dL nonHDLC ≥ 130 mg/dL Fasting triglycerides ≤ 600 mg/dL ( 6.8 mmol/L ) Taking combination background lipidlowering therapy HIV therapy know significant drugdrug interaction NYHA III IV heart failure , last known leave ventricular ejection fraction ( LVEF ) &lt; 30 % Known opportunistic infection/AIDS define illness within 1 year prior randomization Myocardial infarction , unstable angina , percutaneous coronary intervention , coronary artery bypass graft stroke within 3 month Type 1 diabetes , newonset poorly control type 2 diabetes Uncontrolled hypertension Taken cholesterylester transfer protein inhibitor last 12 month Moderate severe renal dysfunction Persistent active liver disease hepatic dysfunction ( Stable chronic hepatitis C least 1 year duration prior randomization allow ) Malignancy ( except nonmelanoma skin cancer , cervical insitu carcinoma , breast ductal carcinoma situ , stage 1 prostate carcinoma ) within last 5 year prior randomization , Other Exclusion Criteria May Apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hyperlipidemia</keyword>
	<keyword>Dyslipidemia</keyword>
	<keyword>Proprotein convertase subtilisin/kexin type 9 ( PCSK9 )</keyword>
	<keyword>Inhibition</keyword>
	<keyword>HIV infection</keyword>
	<keyword>Cluster differentiation</keyword>
	<keyword>Viral load</keyword>
</DOC>